FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168792227> ?p ?o ?g. }

• W3168792227 abstract "Abstract Background The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a non-amplified MAF gene in the primary tumor and benefit from adjuvant zoledronic acid (ZA). Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study. Methods A retrospective analysis of MAF gene status in NSABP B-34 was performed. Eligible patients were randomly assigned to standard adjuvant systemic treatment plus 3-years oral clodronate (1600mg/daily) or placebo. Tumors were tested for MAF gene amplification, and analyzed for their relationship to clodronate for disease-free survival (DFS) and overall survival (OS) in MAF non-amplified patients. All statistical tests were 2-sided. Results . MAF status was assessed in 2,533 available primary tumor samples from 3,311 patients. Of these, 37 withdrew consent; in 77 samples no tumor was found; 536 assays did not meet quality standards, leaving 1,883 (77.8%) evaluable for MAF assay by fluorescence in situ hybridization (947 from placebo, and 936 from clodronate arms). At 5 years, in MAF non-amplified patients receiving clodronate, DFS improved by 30% (hazard ratio =0.70, 95% confidence interval = 0.51-0.94, P=0.02). OS improved at 5 years (hazard ratio =0.59, 95% confidence interval = 0.37–0.93, P=0.02) remaining statistically significant for clodronate throughout study follow-up. Conversely, adjuvant clodronate in women with MAF-amplified tumors was not associated with benefit, but possible harm in some subgroups. Association between MAF status and menopausal status was not seen. Conclusions Non-amplified MAF showed statistically significant benefits (DFS and OS) with oral clodronate, supporting validation of the AZURE study." @default.
• W3168792227 created "2021-06-22" @default.
• W3168792227 creator A5017040191 @default.
• W3168792227 creator A5021077843 @default.
• W3168792227 creator A5024668584 @default.
• W3168792227 creator A5026024346 @default.
• W3168792227 creator A5034546553 @default.
• W3168792227 creator A5034902188 @default.
• W3168792227 creator A5040410256 @default.
• W3168792227 creator A5044108002 @default.
• W3168792227 creator A5046031457 @default.
• W3168792227 creator A5049493074 @default.
• W3168792227 creator A5054057185 @default.
• W3168792227 creator A5055013606 @default.
• W3168792227 creator A5060040445 @default.
• W3168792227 creator A5066444430 @default.
• W3168792227 creator A5074479466 @default.
• W3168792227 creator A5081381927 @default.
• W3168792227 creator A5082509731 @default.
• W3168792227 date "2021-05-28" @default.
• W3168792227 modified "2023-10-16" @default.
• W3168792227 title "<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice" @default.
• W3168792227 cites W1906721103 @default.
• W3168792227 cites W1973580165 @default.
• W3168792227 cites W2003692790 @default.
• W3168792227 cites W2014313639 @default.
• W3168792227 cites W2026290443 @default.
• W3168792227 cites W2113499049 @default.
• W3168792227 cites W2125014991 @default.
• W3168792227 cites W2126357214 @default.
• W3168792227 cites W2138691465 @default.
• W3168792227 cites W2216220193 @default.
• W3168792227 cites W2241843730 @default.
• W3168792227 cites W2314428698 @default.
• W3168792227 cites W2560396365 @default.
• W3168792227 cites W2596883961 @default.
• W3168792227 cites W2624590002 @default.
• W3168792227 cites W2761528352 @default.
• W3168792227 cites W2893634531 @default.
• W3168792227 cites W2945058032 @default.
• W3168792227 cites W2983300662 @default.
• W3168792227 cites W2986158870 @default.
• W3168792227 cites W3048934302 @default.
• W3168792227 cites W4210331534 @default.
• W3168792227 doi "https://doi.org/10.1093/jncics/pkab054" @default.
• W3168792227 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8346694" @default.
• W3168792227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34377934" @default.
• W3168792227 hasPublicationYear "2021" @default.
• W3168792227 type Work @default.
• W3168792227 sameAs 3168792227 @default.
• W3168792227 citedByCount "5" @default.
• W3168792227 countsByYear W31687922272022 @default.
• W3168792227 countsByYear W31687922272023 @default.
• W3168792227 crossrefType "journal-article" @default.
• W3168792227 hasAuthorship W3168792227A5017040191 @default.
• W3168792227 hasAuthorship W3168792227A5021077843 @default.
• W3168792227 hasAuthorship W3168792227A5024668584 @default.
• W3168792227 hasAuthorship W3168792227A5026024346 @default.
• W3168792227 hasAuthorship W3168792227A5034546553 @default.
• W3168792227 hasAuthorship W3168792227A5034902188 @default.
• W3168792227 hasAuthorship W3168792227A5040410256 @default.
• W3168792227 hasAuthorship W3168792227A5044108002 @default.
• W3168792227 hasAuthorship W3168792227A5046031457 @default.
• W3168792227 hasAuthorship W3168792227A5049493074 @default.
• W3168792227 hasAuthorship W3168792227A5054057185 @default.
• W3168792227 hasAuthorship W3168792227A5055013606 @default.
• W3168792227 hasAuthorship W3168792227A5060040445 @default.
• W3168792227 hasAuthorship W3168792227A5066444430 @default.
• W3168792227 hasAuthorship W3168792227A5074479466 @default.
• W3168792227 hasAuthorship W3168792227A5081381927 @default.
• W3168792227 hasAuthorship W3168792227A5082509731 @default.
• W3168792227 hasBestOaLocation W31687922271 @default.
• W3168792227 hasConcept C121608353 @default.
• W3168792227 hasConcept C126322002 @default.
• W3168792227 hasConcept C142724271 @default.
• W3168792227 hasConcept C143998085 @default.
• W3168792227 hasConcept C197934379 @default.
• W3168792227 hasConcept C204787440 @default.
• W3168792227 hasConcept C207103383 @default.
• W3168792227 hasConcept C27081682 @default.
• W3168792227 hasConcept C2777863537 @default.
• W3168792227 hasConcept C44249647 @default.
• W3168792227 hasConcept C530470458 @default.
• W3168792227 hasConcept C71924100 @default.
• W3168792227 hasConcept C90924648 @default.
• W3168792227 hasConceptScore W3168792227C121608353 @default.
• W3168792227 hasConceptScore W3168792227C126322002 @default.
• W3168792227 hasConceptScore W3168792227C142724271 @default.
• W3168792227 hasConceptScore W3168792227C143998085 @default.
• W3168792227 hasConceptScore W3168792227C197934379 @default.
• W3168792227 hasConceptScore W3168792227C204787440 @default.
• W3168792227 hasConceptScore W3168792227C207103383 @default.
• W3168792227 hasConceptScore W3168792227C27081682 @default.
• W3168792227 hasConceptScore W3168792227C2777863537 @default.
• W3168792227 hasConceptScore W3168792227C44249647 @default.
• W3168792227 hasConceptScore W3168792227C530470458 @default.
• W3168792227 hasConceptScore W3168792227C71924100 @default.
• W3168792227 hasConceptScore W3168792227C90924648 @default.
• W3168792227 hasLocation W31687922271 @default.
• W3168792227 hasLocation W31687922272 @default.

• next